Cardiomyocyte USP20 alleviates septic cardiomyopathy by deubiquitinating and inhibiting NLRP3 activity.

Summary

Using cardiomyocyte-specific USP20 knockout and NLRP3 knockout mice with LPS and CLP sepsis models, the authors show that USP20 is downregulated in septic myocardium and that its deficiency worsens cardiac injury. Mechanistically, USP20 removes K63-linked ubiquitin at NLRP3 K243 via its C154 active site, limiting ASC interaction and pyroptosis. AAV9-mediated USP20 overexpression ameliorated myocardial injury, but protection required NLRP3.

Key Findings

• USP20 expression is downregulated in septic myocardium; cardiomyocyte-specific USP20 deficiency exacerbates LPS/CLP-induced cardiac injury and dysfunction.
• USP20 deubiquitinates NLRP3 by removing K63-linked ubiquitin at lysine-243 via its catalytic C154, limiting ASC interaction and downstream pyroptosis.
• AAV9-mediated USP20 overexpression mitigates myocardial injury in vivo; protection is lost in NLRP3 knockout mice, indicating target specificity.

Clinical Implications

USP20–NLRP3 axis modulation could inform future cardioprotective strategies in sepsis, including small-molecule USP20 activators or gene therapy approaches; translation will require human validation and safety profiling.

Limitations

• Preclinical mouse models; absence of human myocardial validation limits immediate translation.
• Potential off-target effects and feasibility of USP20 modulation (e.g., gene therapy) in clinical settings remain uncertain.

Future Directions

Validate USP20–NLRP3 regulation in human septic myocardium; develop selective small-molecule USP20 modulators; test cardioprotective efficacy in large-animal sepsis models.